Design the Pivotal Into the Architecture

Johnson & Johnson cleared the FORTE pivotal milestone for the Ottava soft tissue surgical robot at ASMBS 2026 on May 5, with all primary safety and performance endpoints met across 30 Roux-en-Y gastric bypass patients at six U.S. sites and a 30-day follow-up window. The De Novo classification request is now in front of the FDA, the supporting preclinical package is part of the filing, and the requested coverage spans gastric bypass, sleeve-based procedures, small bowel resection, hiatal hernia repair, and upper abdominal surgery. The structural data point for the surgical robotics ecosystem is the trial design itself. Thirty patients, six sites, thirty days. The field had been operating on the assumption that the soft tissue robotic pivotal was a much heavier enrollment problem than the FORTE design proves, and the founders who learn the right lesson from that data point will be operating with a different cost-and-timeline model than the founders who do not. Founders who finish in surgical robotics design the pivotal trial into the product architecture, before the engineering freeze, alongside the channel diligence and the indication strategy.

If You Are Building a Company in This Environment

The default first-time surgical robotics founder treats the pivotal trial as the regulatory gate that follows engineering completion. The internal logic is that the device freezes at the end of design verification, the regulatory team takes the frozen device and writes the pivotal protocol around the device that exists, and the trial enrolls and runs to whatever endpoint structure the protocol describes. The founders who finish run the operation in the opposite order. The pivotal trial design is the constraint that the device architecture has to satisfy, the indication selection is a decision made years before the engineering freeze, and the regulatory strategy work is interleaved with the product development cadence so that the device that exits design verification is the device that produces the cleanest possible pivotal trial.

The FORTE design is the structural example. A 30-patient single-arm 30-day-follow-up pivotal at six U.S. sites is not an accident of regulatory good fortune. It is the product of an indication selection that produces a clean primary endpoint structure, a procedural workflow that can be standardized across six sites without requiring extensive surgeon-specific training infrastructure, a safety endpoint package that the preclinical data already supports, and a device architecture that is engineered to perform consistently across the six-site, thirty-patient cohort without requiring site-specific calibration or workflow adaptation. Every one of those constraints has to be reflected in the device architecture, and the founders running the pivotal design alongside the architecture work are the ones who arrive at design verification with a device that supports the compact pivotal that the FDA will accept under the De Novo route.

The version of pivotal trial design that breaks first-time surgical robotics founders is the one that begins after the device is frozen. The founder discovers in the pivotal protocol design phase that the indication structure produces an endpoint that requires hundreds of patients, that the procedural workflow varies enough across sites to require a much larger site network, that the safety endpoint package the device supports does not align with the De Novo evidence threshold, and that the architecture choices that produced the device on the development timeline now produce the pivotal trial that will consume two to three additional years and a multiple of the pivotal trial budget the company raised against. The cost of the late pivotal design shows up as a regulatory timeline that is meaningfully longer than the operating plan assumed, and as a capital structure that has to be rebuilt to fund the trial the device actually requires.

The Pattern That Costs Surgical Robotics Founders the Pivotal They Will Need

The pattern that breaks first-time surgical robotics founders on the pivotal trial question is treating regulatory strategy as a downstream function of engineering completion. The pattern produces a predictable timeline. The company raises a Series B against an engineering completion plan and a placeholder pivotal trial budget. The engineering team completes design verification on the schedule the operating plan assumed. The regulatory team then begins writing the pivotal protocol against the device that has just frozen, and the protocol that emerges is the one the device supports rather than the one the indication actually requires. The trial enrollment runs longer than the budget assumed, the site network expands beyond the operating plan, and the De Novo or 510(k) path that the company assumed at Series B becomes the one the FDA actually requires after seeing the protocol the device supports.

The cost shows up at two specific points. The first is in the second commercial round, when the founder discovers that the additional eighteen to thirty months of pivotal trial enrollment compressed the runway against the original capital plan, and the company has to raise a bridge round at a structure that does not reflect the engineering progress the team actually delivered. The second is at the strategic conversation, when the buyer evaluates the platform’s indication breadth and procedural workflow integration on a timeline assumption that the pivotal trial enrollment continues to push out. The integrated commercial story that the strategic acquirers are pricing in 2026 requires the platform to arrive at the strategic conversation with a credible regulatory timeline, and the platforms with the late-design pivotal arrive at that conversation with a regulatory timeline that fights the integration story rather than supporting it.

The companies that finish in this environment do the opposite. They run the pivotal trial design alongside the device architecture decisions from initial product architecture, fund the regulatory strategy work as a Day-1 capital line equivalent in scale to the engineering and channel diligence, and protect it during the busy quarters when the operational pressure is on the engineering build. The work is harder during the run-up to design verification, and it produces the device that arrives at engineering freeze with the pivotal trial structure already engineered into the architecture.

What Pivotal Discipline Looks Like at Operating Scale

The companies that win on the pivotal trial question do specific work that is easy to defer and expensive to skip. They build the indication selection and pivotal protocol design in parallel with the device architecture decisions, identifying every architecture choice that will affect the clean execution of the eventual pivotal across the trial site network. They engage the FDA in pre-submission discussions years before the design verification gate, with a clear understanding of which indication structures support which pivotal trial designs, which device architectures support which evidence packages, and which combinations the FDA device center will accept under the De Novo route versus the 510(k) route versus the PMA route.

At the operating level, the discipline shows up as a structured pivotal trial readiness review that runs alongside the engineering development cadence with the same operating cadence and review intensity. The review includes the indication-specific pivotal trial design model, the alternative indication trade-off model, the FDA pre-submission feedback log, and the architecture-decision impact assessment that maps every engineering decision against its downstream pivotal trial implication. The output is a pivotal protocol design that is ready to file at the moment design verification completes, that produces the cleanest possible enrollment structure for the device the engineering team built, and that fits the De Novo or 510(k) timeline the operating plan funded.

The FORTE structure is the cleanest current example of what the discipline produces on the surgical robotics side. J&J selected an indication where the procedural workflow and the primary endpoint structure support a 30-patient pivotal at six U.S. sites, engineered the Ottava architecture to perform consistently across the cohort and the site network, built the preclinical evidence package that the FDA device center accepts as supporting the safety endpoint, and filed the De Novo request at the moment the pivotal completed the 30-day follow-up window. The same structure exists in cardiac robotic surgery, in interventional cardiology, in endovascular, in flexible bronchoscopy, and in spine, and the founders who finish are the ones who run the pivotal trial design with the same discipline J&J applied to FORTE.

The Five Questions for the Surgical Robotics Pivotal Decision

The five-question framework in Founders Who Finish reframes what a credible regulatory strategy actually requires the team to deliver, and where the operational risk concentrates around the pivotal trial question.